专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR101414333B1 알칼로이드 아미노에스터 유도체 및 그 의약조성물 有权
标题翻译： ALKALOID氨基酸衍生物及其药物组合物
公开(公告)号：KR101414333B1
公开(公告)日：2014-07-02
申请号：KR1020117014392
申请日：2009-12-11
申请人： 키에시 파르마슈티시 엣스. 피. 에이.
发明人： 칼리기우리,안토니오 , 리카보니,마우로 , 아마리,가브리에레
IPC分类号： C07D453/02 , C07D211/46 , A61K31/439 , A61P11/00
CPC分类号： C07D453/02 , C07C233/80 , C07D207/12 , C07D209/02 , C07D211/42 , C07D211/44 , C07D211/46 , C07D223/08 , C07D333/24 , C07D451/10 , C07D491/08
摘要： 본 발명은 무스카린 수용체 길항제로써 작용하는 알칼로이드 아미노에스터 유도체 및 그 유도체의 제조방법, 그것을 포함하는 조성물 및 그것의 치료적 용도에 관한 것이다.

2. 发明授权

KR101378220B1 ＦＧＦ-수용체 효능제 이량체 화합물 有权
标题翻译： FGF-受体激动剂二聚体化合物
公开(公告)号：KR101378220B1
公开(公告)日：2014-03-27
申请号：KR1020087019763
申请日：2007-01-12
申请人： 사노피
发明人： 보노,프랑소와즈 , 귈로,나딸리 , 마프랑,장-삐에르 , 퐁,삐에르 , 올센,야콥-알스뵈크 , 안느-아르샤드,질르
IPC分类号： C07D519/00 , A61K31/435 , A61P11/00 , A61P9/00
CPC分类号： C07D519/00 , A61K31/435 , A61K47/55 , C07D209/02 , C07D221/02
摘要： 본 발명은 화학식 M
1 -LM
2 (식 중, M
1 및 M
2 는 동일하거나 상이할 수 있으며, 각각 서로 독립적으로 단량체 단위 M이고, L은 M
1 과 M
2 를 공유결합에 의해 연결시키는 연결기임)에 상응하는 FGF 수용체 효능제 화합물에 관한 것이며, 여기서 상기 단량체 단위는 하기 (I)과 같은 화학식 M에 상응한다. 본 발명은 또한 이들의 제조 방법 및 치료적 용도에 관한 것이다.
(I)
FGF 수용체 효능제, 헤테로시클릭 화합물, 혈관신생

3. 发明授权

KR101312993B1 히스톤 데아세틸라아제의 억제제 有权
公开(公告)号：KR101312993B1
公开(公告)日：2013-11-25
申请号：KR1020097010969
申请日：2007-10-26
申请人： 메틸진 인코포레이티드 , 포럼 파마슈티칼즈 인크.
发明人： 데지엘,로버트 , 레잇,실바나 , 볼리외,파트릭 , 챈티그니,이브스,안드레 , 만쿠소,존 , 테씨어,피에르 , 샤피로,기데온 , 체스워쓰,리차드 , 스밀,데이비드
IPC分类号： C07D471/04 , C07D291/08 , A61K31/55 , A61P43/00
CPC分类号： C07D498/04 , C07C259/06 , C07C259/10 , C07D209/02 , C07D209/08 , C07D209/52 , C07D209/94 , C07D221/12 , C07D223/16 , C07D223/20 , C07D223/22 , C07D223/24 , C07D223/26 , C07D223/28 , C07D225/08 , C07D239/28 , C07D239/34 , C07D239/42 , C07D243/24 , C07D243/38 , C07D265/38 , C07D267/14 , C07D267/18 , C07D267/20 , C07D279/22 , C07D279/26 , C07D281/16 , C07D285/36 , C07D291/08 , C07D295/155 , C07D313/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D413/06 , C07D413/12 , C07D471/04 , C07D471/08 , C07D471/14 , C07D487/04 , C07D487/08 , C07D487/14 , C07D491/08 , C07D495/04 , C07D513/04 , C07H13/10
摘要： 본 발명은 히스톤 데아세틸라아제의 억제를 위한 화합물에 관한 것이다. 더욱 특히, 본 발명은 하기 화학식(Ｉ)의 화합물을 제공한다:

상기 식에서,

4. 发明公开

KR1020120079037A 신규 유기 반도체 화합물, 그의 제조 방법, 상기를 포함하는 유기 반도체 조성물, 유기 반도체 박막 및 소자 有权
标题翻译：有机半导体化合物，其制备方法和有机半导体组合物，有机半导体薄膜和包括其的器件
公开(公告)号：KR1020120079037A
公开(公告)日：2012-07-11
申请号：KR1020120056688
申请日：2012-05-29
申请人： (주)루미나노
发明人： 한성환 , 조천규
IPC分类号： C07D487/04 , C07D209/82 , H01L51/50 , H01L51/42
CPC分类号： C07D209/02 , C07D209/04 , C07D209/08 , C07D209/26 , C07D209/86 , C07D209/88 , C07D471/22 , C07D487/04 , C07D487/14 , H01L51/0072 , Y02E10/549 , H01L51/0052
摘要： PURPOSE: A novel polycyclic aromatic organic semi-conductor compound and an organic semi-conductor composition containing the same are provided to ensure high crystallinity and solubility in organic solvent and to produce a large amount of semiconductor devices and solar cells. CONSTITUTION: A polycyclic aromatic organic semi-conductor compound is denoted by chemical formula 1. A method for preparing the compound comprises a step of reacting a compound of chemical formula 1' and a compound of chemical formula 2'(R'1-CO-CH2-R'2) in the presence of acid. An organic semi-conductor composition contains one or more polycyclic aromatic organic semi-conductor composition dissolved or dispersed in a solvent. An organic semi-conductor thin film contains the polycyclic aromatic organic semi-conductor compound. A device for electronics, optics, or electron optics contains polycyclic aromatic organic semi-conductor compounds or organic semi-conductor thin film.
摘要翻译：目的：提供一种新型的多环芳族有机半导体化合物和含有它们的有机半导体组合物，以确保在有机溶剂中的高结晶度和溶解度，并产生大量的半导体器件和太阳能电池。构成：化学式1表示多环芳香族有机半导体化合物。制备该化合物的方法包括使化学式1'的化合物与化学式2'的化合物（R'1-CO- CH2-R'2）。有机半导体组合物含有溶解或分散在溶剂中的一种或多种多环芳族有机半导体组合物。有机半导体薄膜含有多环芳族有机半导体化合物。用于电子，光学或电子光学的装置包含多环芳族有机半导体化合物或有机半导体薄膜。

5. 发明公开

KR1020100042296A 펩티드유사 프로테아제 억제제 无效
标题翻译：致敏蛋白抑制剂
公开(公告)号：KR1020100042296A
公开(公告)日：2010-04-23
申请号：KR1020107007138
申请日：2001-08-31
申请人： 버텍스 파마슈티칼스 인코포레이티드
发明人： 베이빈,로버트,에드워드 , 첸,슈,후이 , 라마,제이슨,에릭 , 스나이더,낸시,준 , 선,자이쳉,데이비드 , 테베,마크,조우지프 , 빅토르,프란쯔 , 왕,큐.,메이 , 잎,이본느,예,메이 , 콜라도,이반 , 가르시아-파레데스,크리스티나 , 파커,레이몬드사무엘3세 , 진,링 , 구오,데퀴 , 글래스,존,어빈
IPC分类号： C07C219/24 , C07D401/12 , C07D403/12 , A61P31/12
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds useful as protease inhibitors (1), particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
摘要翻译：本发明涉及可用作蛋白酶抑制剂（1）的拟肽化合物，特别是作为丝氨酸蛋白酶抑制剂，更特别地涉及丙型肝炎NS3蛋白酶抑制剂; 中间体; 它们的制备方法包括对中间体的新型置换步骤。本发明还涉及药物组合物以及使用该化合物抑制HCV蛋白酶或治疗患有HCV感染或感染相关生理状况的患者的方法。还提供了药物组合，除一种或多种HCV丝氨酸蛋白酶抑制剂外还包含一种或多种表现出抗HCV活性的干扰素和/或一种或多种具有抗HCV活性的化合物和药学上可接受的载体，以及用于治疗或预防的方法使用该组合物的患者中的HCV感染。本发明还涉及用于治疗或预防患者HCV感染的试剂盒或药物包装。

6. 发明公开

KR1020090096618A 융합 치환된 아미노피롤리딘 유도체 有权
标题翻译：熔融取代的氨基吡啶衍生物
公开(公告)号：KR1020090096618A
公开(公告)日：2009-09-11
申请号：KR1020097013835
申请日：2007-12-28
申请人： 다이이찌 산쿄 가부시키가이샤
发明人： 다카하시히사시 , 고모리야사토시 , 기타무라다카히로 , 오다기리다카시 , 이나가키히로아키 , 츠다도시후미 , 나카야마기요시 , 다케무라마코토 , 요시다겐이치 , 미야우치리에 , 나가모치마사토시
IPC分类号： C07D498/04 , C07D491/052 , A61K31/47 , A61P31/04
CPC分类号： C07D498/06 , C07D209/02 , C07D209/56 , C07D401/04 , C07D401/14 , C07D491/048 , C07D491/052 , Y02P20/55
摘要： A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.
摘要翻译：提供了作为药物具有优异性能的喹诺酮合成抗菌剂，其不仅对革兰氏阴性细菌具有很强的抗菌活性，而且对喹诺酮抗菌剂的敏感性低的革兰氏阳性球菌具有很强的抗菌活性，并且其表现出高安全性和优异的药代动力学。由式（I）表示的化合物或其盐或其水合物。具体地，其中取代基R6和R7与它们所键合的碳原子一起形成式（I）的喹诺酮衍生物形成可以含有氧原子作为环组成原子的环状结构，所述环状结构形成5- 4,5,5-或5-6稠合双环吡咯烷基取代基，该取代基与含有吡啶并苯并恶嗪结构的喹诺酮母体骨架Q结合。

7. 发明授权

KR100876472B1 펩티드유사 프로테아제 억제제 失效
标题翻译：空值
公开(公告)号：KR100876472B1
公开(公告)日：2008-12-31
申请号：KR1020037002880
申请日：2001-08-31
申请人： 버텍스 파마슈티칼스 인코포레이티드
发明人： 베이빈,로버트,에드워드 , 첸,슈,후이 , 라마,제이슨,에릭 , 스나이더,낸시,준 , 선,자이쳉,데이비드 , 테베,마크,조우지프 , 빅토르,프란쯔 , 왕,큐.,메이 , 잎,이본느,예,메이 , 콜라도,이반 , 가르시아-파레데스,크리스티나 , 파커,레이몬드사무엘3세 , 진,링 , 구오,데퀴 , 글래스,존,어빈
IPC分类号： C07D401/12
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds according to formula 1 useful as protease inhibitors (1), particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective process to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti-HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. a pharmaceutically acceptable salt or prodrug thereof, or a solvate of such a compound, its salt or its prodrug, wherein: R 0 is a bond or difluoromethylene; R 1 is hydrogen, optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group; R 2 and R 9 are each independently optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group; R 3 , R 5 and R 7 are each independently an optionally substituted (1,1- or 1,2-) cycloalkylene, an optionally substituted (1,1- or 1,2-)heterocyclylene, methylene or ethylene, each substituted with one substituent selected from the group consisting -of an optionally substituted aliphatic group, an optionally substituted cyclic group or an optionally substituted aromatic group, and wherein the methylene or ethylene is further optionally substituted with an aliphatic group substituent; R 4 , R 6 , R 8 and R 10 are each independently is hydrogen or optionally substituted aliphatic group; is a substituted monocyclic azaheterocyclyl wherein the unsaturatation is in the ring distal to the ring bearing the R 9 -L-(N(R 8 )-R 7 -C(O)-) n N(R 6 )-R 5 -C(O)-N moiety and to which the -C(O)-N(R 4 )-R 3 -C(O)C(O)NR 2 R 1 moiety is attached; L is -C(O)-, -OC(O)-, -NR 10 C(O)-, -S(O) 2 -, or -NR 10 S(O) 2 -; and n is 0 or 1;
摘要翻译：本发明涉及可用作蛋白酶抑制剂（1）的式1的拟肽化合物，特别是作为丝氨酸蛋白酶抑制剂，更具体地，作为丙型肝炎NS3蛋白酶抑制剂; 中间体; 它们的制备方法包括对中间体的新型置换反应方法。本发明还涉及药物组合物以及使用该化合物抑制HCV蛋白酶或治疗患有HCV感染或感染相关生理状况的患者的方法。还提供了药物组合，除一种或多种HCV丝氨酸蛋白酶抑制剂外还包含一种或多种表现出抗HCV活性的干扰素和/或一种或多种具有抗HCV活性的化合物和药学上可接受的载体，以及用于治疗或使用组合物预防患者的HCV感染。本发明还涉及用于治疗或预防患者HCV感染的试剂盒或药物包装。其药学上可接受的盐或前药，或这种化合物，其盐或其前药的溶剂合物，其中：R 0是键或二氟亚甲基; R 1为氢，任选取代的脂族基团，任选取代的环状基团或任选取代的芳族基团; R 2和R 9各自独立地是任选取代的脂族基团，任选取代的环状基团或任选取代的芳族基团; R 3，R 5和R 7各自独立地为任选取代的（1,1-或1,2-）亚环烷基，任选取代的（1,1-或1,2-）亚杂环，亚甲基或亚乙基，各自被一个取代基，其选自任选取代的脂族基团，任选取代的环状基团或任选取代的芳族基团，并且其中所述亚甲基或亚乙基进一步任选被脂族基团取代基取代; R 4，R 6，R 8和R 10各自独立地为氢或任选取代的脂族基; 是取代的单环氮杂环基，其中不饱和位于带有R 9 -L-（N（R 8）-R 7 -C（O） - ）n N（R 6）-R 5 -C （O）-N部分并且连接有-C（O）-N（R 4）-R 3 -C（O）C（O）NR 2 R 1部分; L是-C（O） - ， - OC（O） - ， - NR 10 C（O） - ， - S（O）2 - 或-NR 10 S（O）并且n为0或1;

8. 发明授权

KR101419085B1 융합 치환된 아미노피롤리딘 유도체 有权
标题翻译：熔融取代的氨基吡啶衍生物
公开(公告)号：KR101419085B1
公开(公告)日：2014-07-15
申请号：KR1020097013835
申请日：2007-12-28
申请人： 다이이찌 산쿄 가부시키가이샤
发明人： 다카하시히사시 , 고모리야사토시 , 기타무라다카히로 , 오다기리다카시 , 이나가키히로아키 , 츠다도시후미 , 나카야마기요시 , 다케무라마코토 , 요시다겐이치 , 미야우치리에 , 나가모치마사토시
IPC分类号： C07D498/04 , C07D491/052 , A61K31/47 , A61P31/04
CPC分类号： C07D498/06 , C07D209/02 , C07D209/56 , C07D401/04 , C07D401/14 , C07D491/048 , C07D491/052 , Y02P20/55
摘要： 의약으로서 우수한 특성을 가진 퀴놀론 합성 항균제가 제공되는데, 이는 그람 음성균뿐 아니라 퀴놀론 항균제에 저 감수성을 가진 그람 양성 구균에도 강한 항균 활성을 가지며, 안전성이 높고 약물동력이 우수하다. 하기 화학식 (I) 로 나타낸 화합물 또는 그의 염 또는 그의 히드레이트가 제공된다. 구체적으로, 치환기 R
6 및 R
7 가 이들이 결합되어 있는 탄소 원자와 함께 취해져 산소 원자를 고리 구성 원자로서 포함할 수 있는 시클릭 구조를 형성하고, 상기 시클릭 구조는 5-4, 5-5 또는 5-6 융합 바이시클릭 피롤리디닐 치환기를 형성하며, 상기 치환기는 피리도벤족사진 구조를 함유하는 퀴놀론 모 골격 Q 에 결합되는 화학식 (I) 의 퀴놀론 유도체이다.

9. 发明公开

KR1020100074081A 신규 유기 반도체 화합물, 그의 제조 방법, 상기를 포함하는 유기 반도체 조성물, 유기 반도체 박막 및 소자 无效
标题翻译：有机半导体化合物，其制备方法和有机半导体组合物，有机半导体薄膜和包括其的器件
公开(公告)号：KR1020100074081A
公开(公告)日：2010-07-01
申请号：KR1020090130240
申请日：2009-12-23
申请人： (주)루미나노
发明人： 한성환 , 조천규
IPC分类号： C07D209/04 , C07D209/02 , H01B1/20
CPC分类号： C07D209/02 , C07D209/04 , C07D209/08 , C07D209/26 , C07D209/86 , C07D209/88 , C07D471/22 , C07D487/04 , C07D487/14 , H01L51/0072 , Y02E10/549
摘要： PURPOSE: A novel polycyclic aromatic organic semiconductor compound is provided to easily control dopping condition in manufacturing an organic semiconductor device. CONSTITUTION: A polycyclic aromatic organic semiconductor is denoted by chemical formula 1. The polycyclic aromatic organic semiconductor compounds is prepared by reacting compound of chemical formula 2'(R'1-CO-CH2-R'2) with a compound of chemical formula 1' under the presence of acid. An organic semiconductor composition contains the polycyclic aromatic organic semiconductor of chemical formula 1 which is dissolved or dispersed in a solvent. An organic semiconductor thin film contains the polycyclic aromatic organic semiconductor of chemical formula 1. An organic filed-effect transistor(OFET) contains the polycyclic aromatic organic semiconductor or organic semiconductor thin film.
摘要翻译：目的：提供一种新型的多环芳族有机半导体化合物，用于在制造有机半导体器件时容易控制掺杂条件。构成：多环芳族有机半导体由化学式1表示。多环芳族有机半导体化合物通过使化学式2'（R'1-CO-CH2-R'2）的化合物与化学式1化合物在酸的存在下。有机半导体组合物包含溶解或分散在溶剂中的化学式1的多环芳族有机半导体。有机半导体薄膜含有化学式1的多环芳族有机半导体。有机场效应晶体管（OFET）含有多环芳族有机半导体或有机半导体薄膜。

10. 发明公开

KR1020100043293A 펩티드유사 프로테아제 억제제 无效
公开(公告)号：KR1020100043293A
公开(公告)日：2010-04-28
申请号：KR1020107007135
申请日：2001-08-31
申请人： 버텍스 파마슈티칼스 인코포레이티드
发明人： 베이빈,로버트,에드워드 , 첸,슈,후이 , 라마,제이슨,에릭 , 스나이더,낸시,준 , 선,자이쳉,데이비드 , 테베,마크,조우지프 , 빅토르,프란쯔 , 왕,큐.,메이 , 잎,이본느,예,메이 , 콜라도,이반 , 가르시아-파레데스,크리스티나 , 파커,레이몬드사무엘3세 , 진,링 , 구오,데퀴 , 글래스,존,어빈
IPC分类号： C07D403/12 , C07D401/12 , A61K31/496 , A61P1/16
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds useful as protease inhibitors (1), particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式